Ammonia control in children ages 2 months through 5 years with urea cycle disorders: Comparison of sodium phenylbutyrate and glycerol phenylbutyrate

Journal of Pediatrics

Volumn 162, Issue 6, 2013, Pages

  Smith, Wendy ^a   Diaz, George A ^b   Lichter Konecki, Uta ^c   Berry, Susan A ^d   Harding, Cary O ^e   McCandless, Shawn E ^f   LeMons, Cindy ^g   Mauney, Joe ^h   Dickinson, Klara ⁱ   Coakley, Dion F ⁱ   Moors, Tristen ⁱ   Mokhtarani, Masoud ⁱ   Scharschmidt, Bruce F ⁱ   Lee, Brendan ^j,k  

^a MAINE MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g National Urea Cycle Disorders Foundation   (United States)

^h Chiltern   (United States)

ⁱ Hyperion Therapeutics   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k HOWARD HUGHES MEDICAL INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; AMMONIA; ARGINASE 1; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; ARGININOSUCCINIC ACID; GLYCEROL PHENYLBUTYRATE; ORNITHINE CARBAMOYLTRANSFERASE;

AMMONIA BLOOD LEVEL; ARGININOSUCCINIC ACIDURIA; ARTICLE; BLOOD ANALYSIS; CHILD; CITRULLINEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CROSSOVER PROCEDURE; FEMALE; FLATULENCE; HEART MURMUR; HUMAN; HYPERARGININEMIA; INFANT; LYMPHADENOPATHY; MALE; NEWBORN; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; UREA CYCLE DISORDER; URINALYSIS; VOMITING;

EID: 84880572675     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2012.11.084     Document Type: Article

References (15)

1. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 1996;43:127-70.
2. Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr 2008;97:1420-5.
3. Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab 2008; 94:397-402.
4. Batshaw ML, Brusilow S, Waber L, Blom W, Brubakk AM, Burton BK, et al. Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med 1982;306:1387-92.
5. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007;356:2282-92.
6. Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 1991;29:147-50.
7. Brusilow SW, Jindelstein J. Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency. Metabolism 1993;42:1336-9.
8. Lee B, Rhead W, Diaz GA, Scharschmidt BF, Mian A, Shchelochkov O, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab 2010;00:221-8.
9. McGuire BM, Zupanets I, Lowe ME, Syplyviy V, Monteleone J, Gargosky S. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010;51:2077-85.
10. Lichter-Konecki U, Diaz GA, Merritt JL II, Feigenbaum A, Jomphe C, Marier JF, et al. Ammonia (NH3) Control in Children with Urea Cycle Disorders (UCDs); Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. Mol Genet Metab 2011;103:323-9.
11. Brusilow S, Tinker J, Batshaw M. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis. Science 1980;207: 659-61.
12. Thibault A, Cooper M, Figg W, Venzon D, Sartor A, Tompkins A, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Research 1994;54:1690-4.
13. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 1995;75:2932-8.
14. Monteleone JPR, Mokhtarani M, Diaz GA, Rhead W, Lichter- Konecki U, Bartley J, et al. Population PK analysis of glycerol phenylbutyrate (GPB) and sodium phenylbutyrate (NaPBA) in adult and pediatric patients with urea cycle disorders (UCD). Molec Genetics and Metab 2012;105:343.
15. Mokhtarani M, Diaz GA, Rhead W, Bartley J, Feigenbaum A, Longo N, et al. Elevated phenylacetic acid (PAA) levels appears linked to neurological adverse events in healthy adults but not in urea cycle disorder (UCD) patients. Mol Genet Metab 2012;105:342.